Gene-Environment Interaction in Parkinson's Disease: Coffee, ADORA2A, and CYP1A2

Overview

Journal Neuroepidemiology

Specialties Neurology
Public Health

Date 2017 Jan 31

PMID 28135712

Citations 23

Authors

Yu-Hsuan Chuang

Christina M Lill

Pei-Chen Lee

Johnni Hansen

Christina F Lassen

Lars Bertram

Naomi Greene

Janet S Sinsheimer

Beate Ritz

Affiliations

Soon will be listed here.

Abstract

Background And Purpose: Drinking caffeinated coffee has been reported to provide protection against Parkinson's disease (PD). Caffeine is an adenosine A2A receptor (encoded by the gene ADORA2A) antagonist that increases dopaminergic neurotransmission and Cytochrome P450 1A2 (gene: CYP1A2) metabolizes caffeine; thus, gene polymorphisms in ADORA2A and CYP1A2 may influence the effect coffee consumption has on PD risk.

Methods: In a population-based case-control study (PASIDA) in Denmark (1,556 PD patients and 1,606 birth year- and gender-matched controls), we assessed interactions between lifetime coffee consumption and 3 polymorphisms in ADORA2A and CYP1A2 for all subjects, and incident and prevalent PD cases separately using logistic regression models. We also conducted a meta-analysis combining our results with those from previous studies.

Results: We estimated statistically significant interactions for ADORA2A rs5760423 and heavy vs. light coffee consumption in incident (OR interaction = 0.66 [95% CI 0.46-0.94], p = 0.02) but not prevalent PD. We did not observe interactions for CYP1A2 rs762551 and rs2472304 in incident or prevalent PD. In meta-analyses, PD associations with daily coffee consumption were strongest among carriers of variant alleles in both ADORA2A and CYP1A2.

Conclusion: We corroborated results from a previous report that described interactions between ADORA2A and CYP1A2 polymorphisms and coffee consumption. Our results also suggest that survivor bias may affect results of studies that enroll prevalent PD cases.

Citing Articles

Microbiome-based therapeutics for Parkinson's disease.

Hamilton A, Krout I, White A, Sampson T Neurotherapeutics. 2024; 21(6):e00462.

PMID: 39393983 PMC: 11585879. DOI: 10.1016/j.neurot.2024.e00462.

Epigenetics: the missing link between environmental exposures and Parkinson's disease?.

Angelopoulou E, Piperi C Epigenomics. 2024; 16(13):921-927.

PMID: 38940212 PMC: 11370972. DOI: 10.1080/17501911.2024.2365615.

The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson's disease.

Gabbert C, Blobaum L, Luth T, Konig I, Caliebe A, Sendel S Sci Rep. 2024; 14(1):14670.

PMID: 38918550 PMC: 11199580. DOI: 10.1038/s41598-024-65640-x.

Impact of genetic predisposition to late-onset neurodegenerative diseases on early life outcomes and brain structure.

Ogonowski N, Garcia-Marin L, Fernando A, Flores-Ocampo V, Renteria M Transl Psychiatry. 2024; 14(1):185.

PMID: 38605018 PMC: 11009228. DOI: 10.1038/s41398-024-02898-9.

The combined effect of lifestyle factors and polygenic scores on age at onset in Parkinson's disease.

Gabbert C, Blobaum L, Luth T, Konig I, Caliebe A, Koch S medRxiv. 2023; .

PMID: 37662355 PMC: 10473779. DOI: 10.1101/2023.08.25.23294466.

References

Hellenbrand W, Seidler A, Boeing H, Robra B, Vieregge P, Nischan P . Diet and Parkinson's disease. I: A possible role for the past intake of specific foods and food groups. Results from a self-administered food-frequency questionnaire in a case-control study. Neurology. 1996; 47(3):636-43. DOI: 10.1212/wnl.47.3.636. View

Hill-Burns E, Hamza T, Zabetian C, Factor S, Payami H . An attempt to replicate interaction between coffee and CYP1A2 gene in connection to Parkinson's disease. Eur J Neurol. 2011; 18(9):e107-8. PMC: 4021852. DOI: 10.1111/j.1468-1331.2011.03464.x. View

Hernan M, Takkouche B, Caamano-Isorna F, Gestal-Otero J . A meta-analysis of coffee drinking, cigarette smoking, and the risk of Parkinson's disease. Ann Neurol. 2002; 52(3):276-84. DOI: 10.1002/ana.10277. View

Ahmed I, Lee P, Lill C, Searles Nielsen S, Artaud F, Gallagher L . Lack of replication of the GRIN2A-by-coffee interaction in Parkinson disease. PLoS Genet. 2014; 10(11):e1004788. PMC: 4238979. DOI: 10.1371/journal.pgen.1004788. View

Pierri M, Vaudano E, Sager T, Englund U . KW-6002 protects from MPTP induced dopaminergic toxicity in the mouse. Neuropharmacology. 2005; 48(4):517-24. DOI: 10.1016/j.neuropharm.2004.11.009. View

Alsene K, Deckert J, Sand P, de Wit H . Association between A2a receptor gene polymorphisms and caffeine-induced anxiety. Neuropsychopharmacology. 2003; 28(9):1694-702. DOI: 10.1038/sj.npp.1300232. View

Hamza T, Chen H, Hill-Burns E, Rhodes S, Montimurro J, Kay D . Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee. PLoS Genet. 2011; 7(8):e1002237. PMC: 3158052. DOI: 10.1371/journal.pgen.1002237. View

Mellick G, Ross O . Caffeine and Parkinson's disease: are we getting our fix on risk-modifying gene-environment interactions?. Eur J Neurol. 2011; 18(5):671-2. DOI: 10.1111/j.1468-1331.2011.03350.x. View

Chen J, Xu K, Petzer J, Staal R, Xu Y, Beilstein M . Neuroprotection by caffeine and A(2A) adenosine receptor inactivation in a model of Parkinson's disease. J Neurosci. 2001; 21(10):RC143. PMC: 6762498. View

10.

Tan E, Lu Z, Fook-Chong S, Tan E, Shen H, Chua E . Exploring an interaction of adenosine A2A receptor variability with coffee and tea intake in Parkinson's disease. Am J Med Genet B Neuropsychiatr Genet. 2006; 141B(6):634-6. DOI: 10.1002/ajmg.b.30359. View

11.

Ross G, Abbott R, Petrovitch H, Morens D, Grandinetti A, Tung K . Association of coffee and caffeine intake with the risk of Parkinson disease. JAMA. 2000; 283(20):2674-9. DOI: 10.1001/jama.283.20.2674. View

12.

Franco R, Ferre S, Agnati L, Torvinen M, Gines S, Hillion J . Evidence for adenosine/dopamine receptor interactions: indications for heteromerization. Neuropsychopharmacology. 2000; 23(4 Suppl):S50-9. DOI: 10.1016/S0893-133X(00)00144-5. View

13.

Ferre S, Quiroz C, Woods A, Cunha R, Popoli P, Ciruela F . An update on adenosine A2A-dopamine D2 receptor interactions: implications for the function of G protein-coupled receptors. Curr Pharm Des. 2008; 14(15):1468-74. PMC: 2424285. DOI: 10.2174/138161208784480108. View

14.

Xu K, Xu Y, Chen J, Schwarzschild M . Neuroprotection by caffeine: time course and role of its metabolites in the MPTP model of Parkinson's disease. Neuroscience. 2010; 167(2):475-81. PMC: 2849921. DOI: 10.1016/j.neuroscience.2010.02.020. View

15.

Facheris M, Schneider N, Lesnick T, de Andrade M, Cunningham J, Rocca W . Coffee, caffeine-related genes, and Parkinson's disease: a case-control study. Mov Disord. 2008; 23(14):2033-40. PMC: 4554698. DOI: 10.1002/mds.22247. View

16.

Popat R, Van Den Eeden S, Tanner C, Kamel F, Umbach D, Marder K . Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease. Eur J Neurol. 2011; 18(5):756-65. PMC: 3556904. DOI: 10.1111/j.1468-1331.2011.03353.x. View

17.

Kenborg L, Lassen C, Ritz B, Andersen K, Christensen J, Schernhammer E . Lifestyle, family history, and risk of idiopathic Parkinson disease: a large Danish case-control study. Am J Epidemiol. 2015; 181(10):808-16. PMC: 4423523. DOI: 10.1093/aje/kwu332. View

18.

Backman J, Schroder M, Neuvonen P . Effects of gender and moderate smoking on the pharmacokinetics and effects of the CYP1A2 substrate tizanidine. Eur J Clin Pharmacol. 2007; 64(1):17-24. DOI: 10.1007/s00228-007-0389-y. View

19.

Byrne E, Johnson J, McRae A, Nyholt D, Medland S, Gehrman P . A genome-wide association study of caffeine-related sleep disturbance: confirmation of a role for a common variant in the adenosine receptor. Sleep. 2012; 35(7):967-75. PMC: 3369232. DOI: 10.5665/sleep.1962. View

20.

Sachse C, Brockmoller J, Bauer S, Roots I . Functional significance of a C-->A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol. 1999; 47(4):445-9. PMC: 2014233. DOI: 10.1046/j.1365-2125.1999.00898.x. View